Spots Global Cancer Trial Database for Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Official Title: Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors
Study ID: NCT00120939
Interventions
Study Description
Brief Summary: The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Contact Details
Name: Gurkamal Chatta, MD
Affiliation: University of Pittsburgh Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
